title: Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.
abstract: Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix() is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 virus-like particles (VLPs) formulated in ASO4 adjuvant. Vaccination with Cervarix has been shown to protect women against a high proportion of precursor lesions of cervical cancer caused by these two HPV types. This review explores the various features of this new vaccine candidate and discusses the future directions in the field of HPV vaccine development.
authors.affiliation: Departments of Pathology.
authors.forename: Archana
authors.initials: A
authors.lastname: Monie
authors.forename: Chien-Fu
authors.initials: CF
authors.lastname: Hung
authors.forename: Richard
authors.initials: R
authors.lastname: Roden
authors.forename: T-C
authors.initials: TC
authors.lastname: Wu
references.citation: J Virol. 1993 Jul;67(7):4154-62
references.pmid: 7685411
references.citation: J Virol. 1993 Jan;67(1):315-22
references.pmid: 8380079
references.citation: Mol Cell. 2000 Mar;5(3):557-67
references.pmid: 10882140
references.citation: J Gen Virol. 1994 Aug;75 ( Pt 8):2075-9
references.pmid: 8046412
references.citation: Virology. 2004 Jun 20;324(1):17-27
references.pmid: 15183049
references.citation: Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11553-7
references.pmid: 8524802
references.citation: J Virol. 1996 Feb;70(2):960-5
references.pmid: 8551636
references.citation: J Infect Dis. 2001 May 15;183(10):1485-93
references.pmid: 11319684
references.citation: Virology. 2000 May 10;270(2):254-7
references.pmid: 10792983
references.citation: N Engl J Med. 2002 Nov 21;347(21):1645-51
references.pmid: 12444178
references.citation: Vaccine. 2006 Jul 7;24(27-28):5571-83
references.pmid: 16753240
references.citation: J Virol. 2007 Nov;81(21):11585-92
references.pmid: 17715230
references.citation: Nat Rev Cancer. 2002 May;2(5):342-50
references.pmid: 12044010
references.citation: J Adolesc Health. 2007 Jun;40(6):564-71
references.pmid: 17531764
references.citation: J Virol. 1995 Jun;69(6):3959-63
references.pmid: 7745754
references.citation: J Virol. 2004 Dec;78(23):12901-9
references.pmid: 15542642
references.citation: Nat Rev Cancer. 2006 Oct;6(10):753-63
references.pmid: 16990853
references.citation: J Virol. 1989 Nov;63(11):4898-903
references.pmid: 2552162
references.citation: Int J Cancer. 2004 Aug 20;111(2):278-85
references.pmid: 15197783
references.citation: Pediatrics. 2006 Nov;118(5):2135-45
references.pmid: 17079588
references.citation: Vaccine. 2006 Aug 14;24(33-34):5937-49
references.pmid: 16828940
references.citation: Virology. 1995 Jan 10;206(1):126-35
references.pmid: 7831768
references.citation: Obstet Gynecol. 2006 Jan;107(1):18-27
references.pmid: 16394035
references.citation: CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
references.pmid: 10200776
references.citation: J Immunol. 2005 Mar 1;174(5):2476-80
references.pmid: 15728450
references.citation: Virology. 1995 Dec 20;214(2):349-59
references.pmid: 8553535
references.citation: Vaccine. 2004 Jul 29;22(21-22):2943-52
references.pmid: 15246631
references.citation: Infect Immun. 2004 Feb;72(2):750-6
references.pmid: 14742517
references.citation: Lancet. 2004 Nov 13-19;364(9447):1757-65
references.pmid: 15541448
references.citation: J Virol. 1997 Apr;71(4):2988-95
references.pmid: 9060658
references.citation: J Virol. 1998 Jul;72(7):6151-4
references.pmid: 9621080
references.citation: Lancet. 2007 Jun 30;369(9580):2161-2170
references.pmid: 17602732
references.citation: Curr Mol Med. 2007 Aug;7(5):490-503
references.pmid: 17691964
references.citation: Vaccine. 2004 Aug 13;22(23-24):3004-7
references.pmid: 15297048
references.citation: J Virol. 2002 Sep;76(17):8900-9
references.pmid: 12163609
references.citation: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4
references.pmid: 1334560
references.citation: Virology. 1992 Sep;190(1):548-52
references.pmid: 1382345
references.citation: Virology. 2001 May 10;283(2):353-7
references.pmid: 11336560
references.citation: Lancet. 2005 Sep 17-23;366(9490):991-8
references.pmid: 16168781
references.citation: Br J Cancer. 2006 Dec 4;95(11):1459-66
references.pmid: 17117182
references.citation: Lancet. 2006 Apr 15;367(9518):1247-55
references.pmid: 16631880
references.citation: Virology. 1996 May 1;219(1):37-44
references.pmid: 8623552
references.citation: Infect Immun. 1997 Aug;65(8):3328-36
references.pmid: 9234794
references.citation: J Virol. 2001 Sep;75(17):7848-53
references.pmid: 11483728
references.citation: J Virol. 2002 Oct;76(19):9798-805
references.pmid: 12208958
references.citation: Vaccine. 2004 Jul 29;22(21-22):2936-42
references.pmid: 15246630
references.citation: Vaccine. 2005 May 25;23(28):3634-41
references.pmid: 15882523
references.citation: J Natl Cancer Inst. 2001 Feb 21;93(4):284-92
references.pmid: 11181775
references.citation: Vaccine. 2006 Mar 15;24(12):2087-93
references.pmid: 16343704
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482